CeriBell (NASDAQ:CBLL) CRO Sells $15,198.72 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 768 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $19.79, for a total transaction of $15,198.72. Following the completion of the transaction, the executive owned 26,933 shares of the company’s stock, valued at approximately $533,004.07. This represents a 2.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CeriBell Price Performance

Shares of CeriBell stock traded down $0.95 during trading on Wednesday, hitting $18.95. 713,550 shares of the company’s stock traded hands, compared to its average volume of 351,326. The company has a market cap of $703.05 million, a PE ratio of -12.55 and a beta of 1.03. The firm’s fifty day moving average price is $21.26 and its 200 day moving average price is $16.17. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $25.98. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Canaccord Genuity Group increased their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Investors Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBLL. Invesco Ltd. raised its stake in shares of CeriBell by 15.5% in the fourth quarter. Invesco Ltd. now owns 12,037 shares of the company’s stock worth $264,000 after acquiring an additional 1,618 shares during the last quarter. Creek Drive Management Group LLC acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $4,253,000. nVerses Capital LLC bought a new position in CeriBell in the 4th quarter worth approximately $282,000. Tudor Investment Corp ET AL acquired a new position in CeriBell during the 4th quarter worth $548,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of CeriBell in the 4th quarter valued at $260,000.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.